JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Начало・Списък с акции・Veracyte Inc

Veracyte Inc

Затворен

СекторЗдравеопазване

35.89 -4.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

35.6

Максимум

37.67

Ключови измерители
By Trading Economics
Приходи	12M 19M
Продажби	1.7M 132M
P/E Средно за сектора	100.421 84.243
Марж на печалбата	14.512
Служители	824
EBITDA	4.4M 24M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+22.76% upside

Дивиденти
By Dow Jones
Следващи печалби	23.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	149M 3B
Предишно отваряне	40.67
Предишно затваряне	35.89

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

30.5 / 31.38 Подкрепа & съпротива

Veracyte Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2026 г., 22:55 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4.02.2026 г., 21:44 ч. UTC

Печалби

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4.02.2026 г., 21:39 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

4.02.2026 г., 23:46 ч. UTC

Печалби

Arm Holdings Expects Slower Revenue Growth in 4Q -- Update

4.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4.02.2026 г., 23:45 ч. UTC

Горещи акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4.02.2026 г., 23:45 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4.02.2026 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4.02.2026 г., 22:30 ч. UTC

Печалби

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4.02.2026 г., 22:30 ч. UTC

Печалби

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4.02.2026 г., 22:21 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4.02.2026 г., 22:15 ч. UTC

Пазарно говорене

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4.02.2026 г., 22:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

4.02.2026 г., 21:53 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4.02.2026 г., 21:51 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.02.2026 г., 21:45 ч. UTC

Печалби

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4.02.2026 г., 21:44 ч. UTC

Печалби

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4.02.2026 г., 21:43 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 21:36 ч. UTC

Пазарно говорене

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Beach Energy Interim Dividend 1 Australian Cent/Sjare

4.02.2026 г., 21:30 ч. UTC

Печалби

Steris Sees FY Adj EPS $10.15-Adj EPS $10.30 >STE

Сравнение с други в отрасъла

Ценова промяна

Veracyte Inc Прогноза

Ценова цел

By TipRanks

22.76% нагоре

12-месечна прогноза

Среден 46.33 USD 22.76%

Висок 50 USD

Нисък 43 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Veracyte Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Veracyte Inc през последните 3 месеца.

Техническа оценка

By Trading Central

30.5 / 31.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.